CITIVA – Shaping the Future of Cannabinoid Medicine
Medical cannabis is something that is often thought of as being a relatively new concept. The truth is that the use of medical cannabis actually dates back thousands of years. CITIVA aims to bring cannabis back into the medical establishment by creating cannabinoid medicines doctors and patients can understand and depend upon. Here at CITIVA, we have more than a century of collective experience in clinical healthcare and medical cannabis, making us a leader in the industry worldwide.
Our prime focus is creating medicines with individualized cannabinoid ratios designed to treat specific diseases and conditions. With help from our partners in academia, we will achieve this through extensive pharmaceutical research and development and proprietary data collection methods. Each of the formulations we develop are designed to meet the most stringent international standards for the development of pharmaceutical drugs.
Some of the conditions cannabinoid medicine has shown effectiveness in treating include:
- AIDS/HIV Treatment
- Amyotrophic Lateral Sclerosis (ALS) Treatment
- Cancer Treatment
- Dravet Syndrome Treatment
- Epilepsy Treatment
- Huntington’s Disease Treatment
- Inflammatory Bowel Disease Treatment
- Multiple Sclerosis Treatment
- Neuropathy Treatment
- Parkinson’s Disease Treatment
- Spinal Cord Damage Treatment
Our goal is to create cutting-edge, cannabinoid-based medicines. We do this by partnering with universities and hospitals to provide research that will help us understand which cannabinoid profiles are best suited to treat specific illnesses and diseases. We work within the law to develop new pharmaceutical products while also raising awareness in an effort to make the use of medical cannabis more widely accepted.
CITIVA’s mission is to deliver naturally sourced cannabinoid therapies that safely reduce suffering and treat disease. Understanding that natural cannabinoids affect the body differently when applied at different ratios, CITIVA sponsors clinical research, through our partners in academia and medicine, to develop products with cannabinoid ratios tailored to treat specific diseases.